Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience-Reference-Cited by-同舟云学术

Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

Published:2021-07-14 Issue: Volume:27 Page:
ISSN:1643-3750
Container-title:Medical Science Monitor
language:en
Short-container-title:Med Sci Monit

Author:

Straś Wojciech¹,Gotlib Joanna²,Małkowski Piotr³,Wasiak Dariusz³,Śliwczyński Andrzej³,Panczyk Mariusz²,Tronina Olga⁴,Brzozowska Melania⁵

Affiliation:

1. Bluefish Pharma, Limited Liability Company, Warsaw, Poland

2. Department of Education and Research of Health Sciences, Medical University of Warsaw, Warsaw, Poland

3. Department of Surgical and Transplantation Nursing and Extracorporeal Therapies, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland

4. Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland

5. Division of Quality Services, Procedures and Medical Standards, Medical University of Łódź, Łódź, Poland

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Experience of Hepatocellular Carcinoma and Their Treatment Goals: An International Qualitative Study and Patient Journey Map;Advances in Therapy;2024-07-25

2. Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review;Cancers;2024-03-27

3. Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth;Frontiers in Pharmacology;2024-01-16

4. Erstlinien-IO-IO-Regime: 4-Jahres-OS-Rate bei 25%;Oncology Research and Treatment;2023